Guggenheim began coverage on shares of Axovant Sciences (NASDAQ:AXGT) in a research report issued to clients and investors on Friday, The Fly reports. The brokerage set a “buy” rating on the stock.

NASDAQ:AXGT opened at $1.19 on Friday. Axovant Sciences has a 52 week low of $0.93 and a 52 week high of $6.59.

Axovant Sciences (NASDAQ:AXGT) last posted its earnings results on Thursday, February 7th. The company reported ($0.27) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.27).

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel therapeutics in the fields of neurology and psychiatry. Its therapeutic focus are Parkinson’s Disease and Lewy Body Dementia. It operates through the following geographical sgements: United States, Switzerland, Bermuda, and Other.

See Also: QQQ ETF

The Fly

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.